These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 37373525

  • 1. Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab.
    Rissel F, Cazaubon Y, Saffar S, Altwegg R, Artasone M, Lozano C, Vincent T, Jentzer A.
    Int J Mol Sci; 2023 Jun 20; 24(12):. PubMed ID: 37373525
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits.
    Laserna-Mendieta EJ, Salvador-Martín S, Marín-Jiménez I, Menchén LA, López-Cauce B, López-Fernández LA, Lucendo AJ.
    J Pharm Biomed Anal; 2021 May 10; 198():114003. PubMed ID: 33714800
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels.
    Pérez I, Fernández L, Sánchez-Ramón S, Alba C, Zatarain A, Cañas M, López ON, Olivares D, Rey E, Taxonera C.
    Therap Adv Gastroenterol; 2018 May 10; 11():1756284818783613. PubMed ID: 30034528
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of two ELISA versions for infliximab serum levels in patients diagnosed with ankylosing spondylitis.
    Hernández-Flórez D, Valor L, de la Torre I, Nieto JC, Martínez-Estupiñán L, González C, López-Longo FJ, Monteagudo I, Garrido J, Naredo E, Carreño L.
    Rheumatol Int; 2015 Jun 10; 35(6):1021-5. PubMed ID: 25410014
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar.
    Jentzer A, Berger AE, Labetoulle R, Haccourt A, Roblin X, Paul S.
    Ther Drug Monit; 2018 Dec 10; 40(6):749-753. PubMed ID: 30439790
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
    Marini JC, Sendecki J, Cornillie F, Popp JW, Black S, Blank M, Gils A, Van Stappen T, Hamann D, Rispens T, Thérien L, Chun K, Shankar G.
    AAPS J; 2017 Jan 10; 19(1):161-171. PubMed ID: 27600137
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.